Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis

Shih Pei Lin, Yi Ting Lee, Shung Haur Yang, Stephanie A. Miller, Shih Hwa Chiou, Mien Chie Hung*, Shih Chieh Hung

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Antiangiogenesis is an efficient therapy for eliminating colon cancers, but because of recurrence it remains only palliative. We hypothesized that certain populations of tumor cells resist antiangiogenesis-induced apoptosis and explored the underlying mechanism. We demonstrated that the CD133+ population of cells in colon cancer is resistant to anti-angiogenesis therapy. Additionally, we identified an anti-apoptotic signaling pathway responsible for this resistance involving PP2A, p38MAPK, MAPKAPK2, and Hsp27. Thus, this pathway may offer a new avenue to develop target therapy for colorectal cancer.

Original languageEnglish
Pages (from-to)226-234
Number of pages9
JournalCancer Letters
Issue number2
StatePublished - 28 Jan 2013


  • Avastin
  • Cancer stem cells
  • Colon cancer
  • Hypoxia
  • Serum-free


Dive into the research topics of 'Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis'. Together they form a unique fingerprint.

Cite this